We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

Challenge yourself regularly

Meet Dmitry Zamoryakhin

Head of Development Strategy & Intelligence

I graduated as a Doctor of Medicine from one of the medical universities in Russia and subsequently completed my specialization in obstetrics and gynecology. I was also fortunate enough to dive into emergency medicine during my student years as I worked in parallel for an intensive care unit at one of the hospitals as well as for the city ambulance where I grew up.

My pharmaceutical career started at the Russian office of GSK in Moscow back in 2003, and it was then that I first encountered terms such as GCP, clinical trials, ethics committees, FDA – you name it! After two years I was invited to move to the headquarters of GSK near London and started working on global clinical programs in the area of infectious diseases including HIV. It was exciting at first, but then I needed a new challenge and moved to a small Japanese company called Ono Pharma. Let me tell you: my learning curve was extraordinary there. My few colleagues and I had to deal with everything from analysis of pre-clinical data to running first-in-man studies, planning and executing phase 2 and 3 studies, medical monitoring, statistics, regulatory work, etc. I then decided to go to a larger Japanese company called Daiichi Sankyo – well, I guess you see kind of an Asian trend developing there (laughs). I spent seven years at Daiichi Sankyo with an increasing number of responsibilities. Together with my manager, we went through the set-up of the European cardiovascular group of the company, piloted a large pediatric program and conducted a number of interesting and unique studies: for example we ran the largest study in kids with sickle cell disease ever conducted; it was done in collaboration with Eli Lilly. And we also participated in a large study exploring post-PCI DAPT in a collaboration with the Food and Drug Administration. This job was where I gained experience in managing large cross-functional matrix teams and learned about the peculiarities of working with colleagues from different cultural backgrounds.

The UK office of Daiichi Sankyo closed down in 2016. Despite several invitations to stay with the company, I chose to change again and joined Grünenthal. After seven years with the same company, it just felt like the right thing to do.

I believe that throughout my career I have gained invaluable experience from working in several therapeutic areas and with various regions, such as the USA, Japan and other Asian countries, the Middle East and Africa. But the most important experience I gained was by working with amazing and highly knowledgeable people. I strongly believe that any company’s future largely depends on the people of the company; they are its most valuable asset.

Get to know Dmitry and find out why he works at Grünenthal.

“A company’s employees are its most valuable asset, and every day I try my best to ensure that the people in my department have top conditions for their work.”

Dmitry Zamoryakhin

Head of Development Strategy & Intelligence

What foremost drives me is my eagerness to learn something new every day. I am convinced that when you become comfortable and settled in your work, you start stagnating; challenging yourself regularly is a sure way to stay sharp at what you do. Then, my desire to improve things and speed up processes: I am adept at the lean approach and try to implement it wherever possible. Last, but not least, I am continuously inspired by working with my colleagues. Currently, we are developing a new operating model for medical devices, which is primarily based on full outsourcing. The aim of the model is to speed up development of medical devices with simultaneous cost reductions. We are also looking into new ways of addressing technical and clinical development plans for medical devices which is a necessary and important part of the development process.

And we are driving innovative projects forward: we are exploring new ways of combining pre-clinical and clinical work to shorten development timelines of devices; we are looking into ground-breaking areas such as digital health and mobile treatment applications; we are reviewing new opportunities in our abuse-deterrent formulation business through partnerships, new in-house projects and more.

Together, we are shaping the future of our company.